Infinity Pharmaceuticals Inc. (INFI) announced after the close Wednesday that Phase 1 clinical data for IPI-145 will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology and the 12th International Conference on Malignant Lymphoma.
Infinity Pharmaceuticals gapped open lower Thursday and has continued to decline in early trade, currently down 3.77 at $27.67. Shares have been falling for the last 2 weeks and have set a 5-month low. The stock has also dropped below its 200-day moving average.
For comments and feedback: editorial@rttnews.com